Taking CBD With Ketamine: What to Know
Epidiolex (Cannabidiol) (also: Charlotte's Web) — Non-psychoactive cannabinoid
Verdict at Tovani Health
Compatible; the CYP3A4 inhibition can slightly raise ketamine levels at high doses.
CBD and ketamine are compatible. CBD is non-psychoactive and does not produce the cannabis interactions covered separately. Two practical considerations: CBD inhibits CYP3A4 and CYP2C19 (the enzymes that metabolize ketamine), so at high doses it can modestly raise ketamine plasma levels; and CBD products are unregulated, so potency varies significantly between brands.
If you take Epidiolex regularly and are considering at-home ketamine therapy, the combination is safe with monitoring or modest dose adjustment. This page covers the brief pharmacologic context and what we do at intake.
How Epidiolex interacts with ketamine
CBD binds many targets weakly (CB1 negative allosteric modulator, 5-HT1A agonist, others). It inhibits CYP3A4 and CYP2C19 at clinically relevant doses, which can affect metabolism of other drugs.
What we do at intake
Disclose dose, brand, and route (oil, gummies, vape). High-dose Epidiolex (prescription, 10-20 mg/kg/day) has more interaction potential than typical OTC CBD doses (10-50 mg/day).
Bottom line
CBD and ketamine are compatible. CBD is non-psychoactive and does not produce the cannabis interactions covered separately. Two practical considerations: CBD inhibits CYP3A4 and CYP2C19 (the enzymes that metabolize ketamine), so at high doses it can modestly raise ketamine plasma levels; and CBD products are unregulated, so potency varies significantly between brands.
Frequently Asked Questions
Is CBD the same as cannabis for KAP planning?
No. CBD is non-psychoactive and has a much lighter interaction profile than THC-containing cannabis.
Ready to find out if at-home ketamine fits your situation?
We’ll note that you’re on Epidiolex (Cannabidiol) at intake. The eligibility check takes 5 minutes and gives you an honest answer about whether at-home ketamine fits your specific situation.
FL and NJ residents only. Benjamin Soffer, DO — Tovani Health.
Sources
The verdict and clinical guidance on this page are based on the following peer-reviewed literature and FDA prescribing information.
- Evaluation of Cytochrome P450-Mediated Cannabinoid-Drug Interactions in Healthy Adult Participants. Bansal S, Zamarripa CA, Spindle TR. Clinical Pharmacology and Therapeutics. 2023. PMID: 37313955
- Comprehensive Predictions of Cytochrome P450 (P450)-Mediated In Vivo Cannabinoid-Drug Interactions Based on Reversible and Time-Dependent CYP Inhibition. Bansal S, Paine MF, Unadkat JD. Drug Metabolism and Disposition. 2022. PMID: 35115300
Clinically reviewed
Reviewed by Benjamin Soffer, DO on May 16, 2026. Dr. Soffer is a board-certified physician (American Board of Internal Medicine) licensed in Florida and New Jersey, prescribing at-home ketamine therapy through Tovani Health.
This page is general information about how this medication interacts with at-home ketamine therapy at Tovani Health. It is not a substitute for medical advice from your prescribing physician about your specific situation. Always discuss medication changes with the doctor who prescribed them.